CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


CyclosporineWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug912 Non-invasive cardiac imaging Wiki 1.00

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D002318 Cardiovascular Diseases NIH 0.24

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Phase I Trial for the Prevention of Cytokine Release Syndrome (CRS) With Cyclosporine in Patients With Moderate COVID-19

Phase 1 safety study to determine the tolerability, clinical effects, and changes in laboratory parameters of short course oral or IV cyclosporine (CSA) administration in patients with COVID-19 disease requiring oxygen supplementation but not requiring ventilator support.

NCT04412785 COVID-19 Drug: Cyclosporine

Primary Outcomes

Description: Safety will be measured: By assessing the proportion of participants requiring increase in oxygen requirements, transfer to intensive care unit, and/or mechanical ventilation

Measure: Safety-oxygen, ICU transfer and ventilation

Time: 3 months

Description: Safety will be assessed: By monitoring changes in absolute lymphocyte counts

Measure: Safety-changes in absolute lymphocyte count

Time: 3 months

Description: Safety will be assessed: By monitoring changes in creatinine clearance. Creatinine clearance will be estimated using the Cockcroft-Gault formula.

Measure: Safety-changes in creatinine clearance

Time: 3 months

Description: Safety will be assessed: By monitoring the incidence of secondary bacterial infections complicating COVID-19 hospitalization

Measure: Safety-secondary bacterial infections

Time: 3 months

Secondary Outcomes

Description: To measure time to SARS-CoV-2 clearance (PCR negativity) at Days 7 and 14 by deep nasal swab

Measure: Laboratory measurements of safety and antiviral efficacy related to COVID-19-SARS-CoV-2 by measuring the clearance of SARS-CoV-2 from respiratory secretions

Time: 3 months

Description: To measure the laboratory correlatives of CRS/ Hemophagocytic lymphohistiocytosis (HLH) by measuring: D-dimer levels

Measure: Laboratory measurements-D-dimer levels

Time: 3 months

Description: To measure the laboratory correlatives of CRS/ Hemophagocytic lymphohistiocytosis (HLH) by measuring: ferritin levels

Measure: Laboratory measurements-ferritin

Time: 3 months

Description: To measure the laboratory correlatives of CRS/ Hemophagocytic lymphohistiocytosis (HLH) by measuring: IL-6 levels

Measure: Laboratory measurements- IL-6

Time: 3 months


No related HPO nodes (Using clinical trials)